Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $28.28.

A number of equities analysts recently issued reports on the stock. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. JMP Securities boosted their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research report on Wednesday, January 31st. Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Wednesday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday.

Kura Oncology Stock Up 3.0 %

NASDAQ:KURA opened at $18.73 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. The firm’s 50-day moving average price is $20.73 and its 200-day moving average price is $15.35. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a market capitalization of $1.43 billion, a PE ratio of -9.00 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. During the same quarter in the prior year, the business earned ($0.49) EPS. On average, equities analysts predict that Kura Oncology will post -2.35 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Teresa Brophy Bair sold 2,053 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $36,543.40. Following the completion of the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at approximately $1,227,826.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Teresa Brophy Bair sold 2,053 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $36,543.40. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,227,826.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kathleen Ford sold 1,496 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $26,628.80. Following the completion of the transaction, the chief operating officer now owns 21,602 shares of the company’s stock, valued at $384,515.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,867 shares of company stock valued at $104,433. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently modified their holdings of the stock. 1492 Capital Management LLC grew its position in Kura Oncology by 1.0% during the fourth quarter. 1492 Capital Management LLC now owns 101,500 shares of the company’s stock valued at $1,460,000 after buying an additional 1,034 shares during the period. E Fund Management Co. Ltd. lifted its stake in shares of Kura Oncology by 12.2% in the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after purchasing an additional 1,301 shares during the last quarter. Arizona State Retirement System lifted its position in Kura Oncology by 9.8% in the third quarter. Arizona State Retirement System now owns 15,823 shares of the company’s stock valued at $144,000 after buying an additional 1,406 shares during the last quarter. Signaturefd LLC boosted its position in shares of Kura Oncology by 40.4% during the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after purchasing an additional 1,449 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in shares of Kura Oncology by 11.1% during the third quarter. Teacher Retirement System of Texas now owns 15,490 shares of the company’s stock worth $141,000 after buying an additional 1,544 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.